Yu-Chieh Ho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yu-Chieh Ho has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Hsuan-Yu Lin
Department of Psychology, Faculty of Human and Health Sciences, University of Bremen, Bremen, Germany
2 shared publications - Jhen-Bin Lin
Department of Radiation Oncology, Changhua Christian Hospital, Changhua, Taiwan
2 shared publications Chia-Chun Huang
Department of Radiation Oncology, Changhua Christian Hospital, Changhua, Taiwan
1 shared publication- Chia-Chun Huang
Department of Radiation Oncology, Changhua Christian Hospital, Changhua 500, Taiwan
1 shared publication Jin-Ching Lin
Department of Radiation Oncology, Changhua Christian Hospital, Changhua, Taiwan
1 shared publication- Jin-Ching Lin
Changhua Christian Hospital
1 shared publication
Latest Publications
- Open Access
Cardiac Dose Predicts the Response to Concurrent Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
Definitive concurrent chemoradiation (CCRT) is the standard treatment for cervical esophageal cancer and non-surgical candidates. Initial treatment response affects survival; however, few validated markers are available for prediction. This study evaluated the clinical variables and chemoradiation parameters associated with treatment response. Between May 2010 and April 2016, 86 completed CCRT patients’ clinical, dosimetric, and laboratory data at baseline and during treatment were collected. Cox regression analysis assessed the risk factors for overall survival (OS). A receiver operating characteristic curve with Youden’s index was chosen to obtain the optimal cut-off value of each parameter. Treatment response was defined per Response Evaluation Criteria in Solid Tumors v.1.1 at the first post-CCRT computed tomography scan. Responders had complete and partial responses; non-responders had stable and progressive diseases. Logistic regression (LR) was used to evaluate the variables associated with responders. The Cox regression model confirmed the presence of responders (n = 50) vs. non-responders (n = 36) with a significant difference in OS. In multivariate LR, cardiac dose–volume received ≥10 Gy; the baseline hemoglobin level, highest neutrophil to lymphocyte ratio during CCRT, and cumulative cisplatin dose were significantly associated with the responders. The initial clinical treatment response significantly determines disease outcome. Cardiac irradiation may affect the treatment response.
Open AccessCardiac Dose Predicts the Response to Concurrent Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
Definitive concurrent chemoradiation (CCRT) is the standard treatment for cervical esophageal cancer and non-surgical candidates. Initial treatment response affects survival; however, few validated markers are available for prediction. This study evaluated the clinical variables and chemoradiation parameters associated with treatment response. Between May 2010 and April 2016, 86 completed CCRT patients’ clinical, dosimetric, and laboratory data at baseline and during treatment were collected. Cox regression analysis assessed the risk factors for overall survival (OS). A receiver operating characteristic curve with Youden’s index was chosen to obtain the optimal cut-off value of each parameter. Treatment response was defined per Response Evaluation Criteria in Solid Tumors v.1.1 at the first post-CCRT computed tomography scan. Responders had complete and partial responses; non-responders had stable and progressive diseases. Logistic regression (LR) was used to evaluate the variables associated with responders. The Cox regression model confirmed the presence of responders (n = 50) vs. non-responders (n = 36) with a significant difference in OS. In multivariate LR, cardiac dose–volume received ≥10 Gy; the baseline hemoglobin level, highest neutrophil to lymphocyte ratio during CCRT, and cumulative cisplatin dose were significantly associated with the responders. The initial clinical treatment response significantly determines disease outcome. Cardiac irradiation may affect the treatment response.
- Open Access
- 1 June 2021
- Published by AME Publishing Company in Therapeutic Radiology and Oncology
- Vol. 5, 9
The volume of low-dose thoracic irradiation influences systemic inflammation-immunity status after chemoradiation in esophageal cancer
Background: Definitive chemoradiation is an essential treatment for non-operative thoracic esophageal cancer. However, it may trigger radiation-induced lymphopenia, impacting survival outcomes. The neutrophil-lymphocyte ratio (NLR) is an indicator of inflammatory status and survival outcomes. Here, we determined the association of clinical and dosimetric parameters with changes in hematological variables. Methods: We recruited 93 thoracic esophageal squamous-cell cancer patients who have completed definitive concurrent chemoradiotherapy (CCRT) between 2010 and 2015. Clinical, dosimetric, and hematological data, including absolute neutrophil count (ANC), absolute lymphocyte count (ALC), and NLR, were analyzed at baseline and during CCRT. Cox regression model and Kaplan-Meier analyses were used to analyze different survival outcomes. Associations between clinical, hematological, and dosimetric variables were determined using Spearman’s rank or Pearson correlation coefficients, and a multivariable logistic regression was used to verify identified correlations. Results: Patients (mean age =58.6 y) were predominantly males (94%), 27% of which were stage II (n=25) and 73% were stage III (n=68), with a median overall survival (OS) of 13 months [95% confidence interval (CI): 10.304–15.696]. Baseline NLR (NLR-b) and highest NLR during CCRT (NLR-h) was significantly correlated with OS, progression-free survival (PFS), disease-specific survival (DSS), and freedom from distant metastasis (FFDM). Dichotomized NLR-b, >3.68 or ≤3.68, was also correlated with survival. Primary esophageal tumor length (Spearman’s r=0.324, P=0.011) and baseline body weight (Spearman’s r=–0.251, P=0.019) were significantly correlated with NLR-b >3.68. In multivariable logistic regression, primary esophageal tumor length (OR =1.345, P=0.021) was associated with a higher NLR-b. Lung V5 (Pearson r=0.254, P=0.014) and V10 (Pearson r=0.317, P=0.002) were significantly correlated with NLR-h. Lung V5 (Pearson r=0.299, P=0.005) and heart V10 (Pearson r=0.273, P=0.011) were significantly correlated with the decrease in ALC during CCRT. Conclusions: Status of inflammation is correlated with survival outcomes and tumor size, and low-dose thoracic irradiation affects inflammation-immunity dynamics. A novel approach that decreases unnecessary exposures to radiation may further improve survival outcomes in esophageal cancer treated with CCRT.
- 1 June 2021
- Published by AME Publishing Company in Therapeutic Radiology and Oncology
- Vol. 5, 9
Open AccessThe volume of low-dose thoracic irradiation influences systemic inflammation-immunity status after chemoradiation in esophageal cancer
Background: Definitive chemoradiation is an essential treatment for non-operative thoracic esophageal cancer. However, it may trigger radiation-induced lymphopenia, impacting survival outcomes. The neutrophil-lymphocyte ratio (NLR) is an indicator of inflammatory status and survival outcomes. Here, we determined the association of clinical and dosimetric parameters with changes in hematological variables. Methods: We recruited 93 thoracic esophageal squamous-cell cancer patients who have completed definitive concurrent chemoradiotherapy (CCRT) between 2010 and 2015. Clinical, dosimetric, and hematological data, including absolute neutrophil count (ANC), absolute lymphocyte count (ALC), and NLR, were analyzed at baseline and during CCRT. Cox regression model and Kaplan-Meier analyses were used to analyze different survival outcomes. Associations between clinical, hematological, and dosimetric variables were determined using Spearman’s rank or Pearson correlation coefficients, and a multivariable logistic regression was used to verify identified correlations. Results: Patients (mean age =58.6 y) were predominantly males (94%), 27% of which were stage II (n=25) and 73% were stage III (n=68), with a median overall survival (OS) of 13 months [95% confidence interval (CI): 10.304–15.696]. Baseline NLR (NLR-b) and highest NLR during CCRT (NLR-h) was significantly correlated with OS, progression-free survival (PFS), disease-specific survival (DSS), and freedom from distant metastasis (FFDM). Dichotomized NLR-b, >3.68 or ≤3.68, was also correlated with survival. Primary esophageal tumor length (Spearman’s r=0.324, P=0.011) and baseline body weight (Spearman’s r=–0.251, P=0.019) were significantly correlated with NLR-b >3.68. In multivariable logistic regression, primary esophageal tumor length (OR =1.345, P=0.021) was associated with a higher NLR-b. Lung V5 (Pearson r=0.254, P=0.014) and V10 (Pearson r=0.317, P=0.002) were significantly correlated with NLR-h. Lung V5 (Pearson r=0.299, P=0.005) and heart V10 (Pearson r=0.273, P=0.011) were significantly correlated with the decrease in ALC during CCRT. Conclusions: Status of inflammation is correlated with survival outcomes and tumor size, and low-dose thoracic irradiation affects inflammation-immunity dynamics. A novel approach that decreases unnecessary exposures to radiation may further improve survival outcomes in esophageal cancer treated with CCRT.